glp 1 compound ending The FDA has proposed to bar 503B outsourcing facilities from bulk compounding semaglutide and tirzepatide. The shortage-list pathway already closed in 2024 and 2025; this proposal would remove the remaining bulks-list route It's important to study the

All three need to be looked at in mechanistic studies. The researchers acknowledged study limitations, including its retrospective design and use of a U.S.-based database

As people eat less and lose weight (left side), they may develop nutrient deficiencies such as low vitamin D, iron-deficiency anemia, or even muscle loss (middle)

Newsome et al

Dungan & DeSantis, 2026)

Based on several clinical studies documenting the effects of liraglutide, a long-lasting GLP-1RAs, on weight loss, it has been approved for the treatment of obesity at a dose of 3.0 mg/day in the form of subcutaneous injections [88]

Changes to Medicare and Medicaid linked to the TrumpRx initiative are structured as phased implementations that expand coverage and negotiate co-pay structures, with significant milestones anticipated through 20252026